RS50681B - Kombinacija taksana i ciklin-zavisne kinaze - Google Patents

Kombinacija taksana i ciklin-zavisne kinaze

Info

Publication number
RS50681B
RS50681B YUP-695/03A YUP69503A RS50681B RS 50681 B RS50681 B RS 50681B YU P69503 A YUP69503 A YU P69503A RS 50681 B RS50681 B RS 50681B
Authority
RS
Serbia
Prior art keywords
taxotere
combination
days
dose
tumor
Prior art date
Application number
YUP-695/03A
Other languages
English (en)
Serbian (sr)
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of YU69503A publication Critical patent/YU69503A/sh
Publication of RS50681B publication Critical patent/RS50681B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
YUP-695/03A 2001-03-23 2002-03-22 Kombinacija taksana i ciklin-zavisne kinaze RS50681B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US30269201P 2001-07-05 2001-07-05
US33491601P 2001-12-04 2001-12-04

Publications (2)

Publication Number Publication Date
YU69503A YU69503A (sh) 2006-08-17
RS50681B true RS50681B (sr) 2010-06-30

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-695/03A RS50681B (sr) 2001-03-23 2002-03-22 Kombinacija taksana i ciklin-zavisne kinaze

Country Status (33)

Country Link
US (2) US20020182204A1 (enExample)
EP (1) EP1372652B1 (enExample)
JP (1) JP2004521140A (enExample)
KR (1) KR100879712B1 (enExample)
CN (1) CN1498107A (enExample)
AR (1) AR034222A1 (enExample)
AT (1) ATE395917T1 (enExample)
AU (1) AU2002312815B2 (enExample)
BR (1) BR0208221A (enExample)
CA (1) CA2441441C (enExample)
CY (1) CY1110449T1 (enExample)
CZ (1) CZ301423B6 (enExample)
DE (1) DE60226710D1 (enExample)
DK (1) DK1372652T3 (enExample)
EA (1) EA007815B1 (enExample)
ES (1) ES2305253T3 (enExample)
HR (1) HRPK20030766B3 (enExample)
HU (1) HU229258B1 (enExample)
IL (2) IL158058A0 (enExample)
ME (1) MEP16408A (enExample)
MX (1) MXPA03007743A (enExample)
NO (1) NO332441B1 (enExample)
NZ (1) NZ527655A (enExample)
PE (1) PE20020907A1 (enExample)
PL (1) PL206118B1 (enExample)
PT (1) PT1372652E (enExample)
RS (1) RS50681B (enExample)
SI (1) SI1372652T1 (enExample)
SK (1) SK287481B6 (enExample)
TW (1) TWI355935B (enExample)
UY (1) UY27220A1 (enExample)
WO (1) WO2002076484A2 (enExample)
ZA (1) ZA200307381B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487434B1 (en) * 2002-03-06 2007-05-09 The Medical Research and Education Trust Botanical extract compositions with anti-cancer activity comprising isoliquiritigenin
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
JP4764165B2 (ja) * 2002-11-06 2011-08-31 サイクラセル リミテッド ドセタキセル及びｃｄｋ阻害剤を含む組合せ
EP1986632B1 (en) * 2006-02-10 2012-08-15 Nerviano Medical Sciences S.R.L. Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
CN104220066A (zh) * 2010-11-19 2014-12-17 皮拉马尔企业有限公司 紫杉醇和cdk抑制剂药物组合物
JP6080837B2 (ja) * 2011-04-01 2017-02-15 アストラゼネカ アクチボラグ 療法的治療
KR102035361B1 (ko) 2011-11-30 2019-11-08 아스트라제네카 아베 암의 병용 치료
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers

Also Published As

Publication number Publication date
KR100879712B1 (ko) 2009-01-22
JP2004521140A (ja) 2004-07-15
CZ20032551A3 (en) 2004-07-14
YU69503A (sh) 2006-08-17
TWI355935B (en) 2012-01-11
PE20020907A1 (es) 2002-12-19
CA2441441C (en) 2009-05-26
DE60226710D1 (de) 2008-07-03
ZA200307381B (en) 2005-03-30
NO20034124D0 (no) 2003-09-16
NO20034124L (no) 2003-09-16
CN1498107A (zh) 2004-05-19
EP1372652A2 (en) 2004-01-02
MEP16408A (en) 2010-10-10
PL367702A1 (en) 2005-03-07
SK11692003A3 (sk) 2004-03-02
BR0208221A (pt) 2004-03-02
NZ527655A (en) 2006-03-31
AR034222A1 (es) 2004-02-04
SK287481B6 (sk) 2010-11-08
HUP0303589A2 (hu) 2004-03-01
IL158058A (en) 2010-02-17
ATE395917T1 (de) 2008-06-15
WO2002076484A2 (en) 2002-10-03
MXPA03007743A (es) 2004-11-12
CZ301423B6 (cs) 2010-02-24
CA2441441A1 (en) 2002-10-03
HRP20030766A2 (en) 2005-06-30
IL158058A0 (en) 2004-03-28
AU2002312815B2 (en) 2006-08-24
US20020182204A1 (en) 2002-12-05
UY27220A1 (es) 2002-09-30
WO2002076484A3 (en) 2003-01-03
EA007815B1 (ru) 2007-02-27
HRPK20030766B3 (en) 2006-11-30
EA200301053A1 (ru) 2004-02-26
HUP0303589A3 (en) 2007-05-02
CY1110449T1 (el) 2015-04-29
ES2305253T3 (es) 2008-11-01
SI1372652T1 (sl) 2008-10-31
EP1372652B1 (en) 2008-05-21
US20060128640A1 (en) 2006-06-15
PL206118B1 (pl) 2010-07-30
DK1372652T3 (da) 2008-09-22
NO332441B1 (no) 2012-09-17
KR20030086318A (ko) 2003-11-07
HU229258B1 (en) 2013-10-28
PT1372652E (pt) 2008-07-24

Similar Documents

Publication Publication Date Title
Li et al. Systemic chemotherapy for the treatment of metastatic melanoma
CZ288033B6 (cs) Sdružená kompozice paclitaxelu, docetaxelu nebo jejich analogu
CA2538218A1 (en) Compositions of botanical extracts for cancer therapy
US20160279094A1 (en) Dietary and natural product management of negative side effects of cancer treatment
RS50681B (sr) Kombinacija taksana i ciklin-zavisne kinaze
AU2002312815A1 (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
EP2046323A2 (en) Methods, compositions and articles of manufacture for contributing to the treatment of cancers
Di Cosimo et al. Docetaxel in advanced gastric cancer review of the main clinical trials
EP1007029A1 (en) Methods and compositions for treatment of ovarian cancer
AU2004241889B2 (en) Migraine remedy
Govindan Management of patients with non-small cell lung cancer and poor performance status
Cosimo et al. Docetaxel in Advanced Gastric Cancer.
Relias et al. Topoisomerase I inhibitors: 1. Topotecan
Bishop Scheduling of chemotherapy and radiotherapy in locally advanced non-small cell lung cancer
Scheithauer et al. The role of oxaliplatin in the management of upper gastrointestinal tract malignancies
CN116531395A (zh) 含青蒿素类衍生物的组合物及在制备治疗白血病药物中的应用
Tilanus et al. CISPLATIN AND ETOPOSIDE IN